ClinicalTrials.gg
CompletedNCT01157351Updated Apr 24, 2015Results posted

15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated

A Phase 4 interventional study of paliperidone and risperidone in Schizophrenia, sponsored by Janssen Scientific Affairs, LLC. Completed at 56 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-04-24.

Sponsored by Janssen Scientific Affairs, LLC (part of Johnson & Johnson) · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.

Enrollment
22nd of 115
450 · median 178
Started
2010
with 7 others
Phase 4
42 of 115
5 open now
Registered
57th of 115
by date

Among the 115 studies testing paliperidone in Schizophrenia, this one is the 22nd largest by enrollment, is one of 8 that started in 2010, is one of 42 in phase 4, and was the 57th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About paliperidone

paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies testing paliperidone in Schizophrenia, or all of them as a file.
02

Study summary

The study will assess the use of paliperidone palmitate compared with oral antipsychotic treatment in delaying time to a protocol-defined treatment failure over 15 months, in patients diagnosed with schizophrenia who have been incarcerated.

Read the detailed description

The primary objective of this study is to compare the efficacy of paliperidone palmitate with oral antipsychotic treatment in delaying time to a protocol-defined treatment failure over 15 months, in patients diagnosed with schizophrenia who have been incarcerated. Protocol-defined treatment failure is defined as arrest, psychiatric hospitalization, increase in psychiatric services to prevent imminent hospitalization, discontinuation of antipsychotic treatment due to inadequate efficacy, treatment supplementation with another antipsychotic due to inadequate efficacy, discontinuation of antipsychotic treatment due to safety or tolerability or completed suicide. Protocol was amended on March 15, 2011 to reflect changes in the inclusion/exclusion criteria as well as the study objectives. Patients will receive either paliperidone palmitate 78, 117, 156, or 234 mg monthly by injection for fifteen months OR oral aripiprazole, haloperidol, olanzapine, paliperidone, perphenazine, quetiapine, and risperidone at doses selected by the study doctor.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • Risperidone
  • Risperdal
  • Paliperidone palmitate
  • Aripiprazole
  • Haloperidol
  • Olanzapine
  • Paliperidone
  • Perphenazine
  • Quetiapine
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be able to understand and sign the form approved by the Institutional Review Board (IRB)
  • Must successfully answer all the questions on the Informed Consent quiz indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study
  • Have a current diagnosis of schizophrenia
  • Taking no more than 1 oral antipsychotic on the day before randomization
  • Have been placed into custody at least twice with one of them leading to incarceration within the 24 months previous to study start, with the last release occurring within the 90 days before the first day of screening
  • in the opinion of the investigator, may benefit from a change in their prior antipsychotic treatment
  • Have available a designated individual (eg, family member, case manager, significant other, probation/parole officer) who has knowledge of the patient and is generally aware of the patient's daily activities, and who agrees to let the study site personnel know of changes in the patients circumstances when the patient is not able to provide this information, ie, arrests, protocol-defined hospitalizations, emergency room visits, becoming homeless, etc.
  • Have either an address or phone number where they can be reached, or be accessible to the designated individual
  • Must agree to receive regular injections for 15 months if randomly assigned to the paliperidone palmitate treatment group, or continue with oral study medication treatment for 15 months if randomly assigned to the oral antipsychotic treatment group
  • Women must be (for at least 2 years), surgically sterile (hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy), abstinent, or if sexually active, be practicing a highly effective method of

Exclusion criteria

Exclusion Criteria:

  • Allergies, (anaphylaxis-type reaction), or intolerance to risperidone or paliperidone
  • Actively abusing intravenous drugs within the past 3 months or have an opiate dependence disorder
  • Have a positive urine drug screen test for barbiturates, cocaine, amphetamines, or opiates at screening
  • Women who are pregnant or breast-feeding, or planning to become pregnant
  • Have received injectable antipsychotic treatment within 2 injection cycles prior to screening
  • Received treatment with clozapine within 3 months of screening
  • Are at a high risk of violence in the next 15 months, in the opinion of the investigator
  • who have a history of sex offenses including felony sex offenses, child molestation
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
450 participants (actual)

Study arms

  • Experimental
    001

    paliperidone palmitate 78 117 156 or 234 mg monthly injection for 15 months

    Drug: paliperidone palmitate

  • Active comparator
    002

    aripiprazole flexible dosing as prescribed by the study doctor for 15 months

    Drug: aripiprazole

  • Active comparator
    003

    haloperidole flexible dosing as prescribed by the study doctor for 15 months

    Drug: haloperidole

  • Active comparator
    004

    olanzapine flexible dosing as prescribed by the study doctor for 15 months

    Drug: olanzapine

  • Active comparator
    005

    paliperidone flexible dosing as prescribed by the study doctor for 15 months

    Drug: paliperidone

  • Active comparator
    006

    perphenazine flexible dosing as prescribed by the study doctor for 15 months

    Drug: perphenazine

  • Active comparator
    007

    quetiapine flexible dosing as prescribed by the study doctor for 15 months

    Drug: quetiapine

  • Active comparator
    008

    risperidone flexible dosing as prescribed by the study doctor for 15 months

    Drug: risperidone

Interventions

  • flexible dosing as prescribed by the study doctor for 15 months

  • flexible dosing as prescribed by the study doctor for 15 months

  • flexible dosing as prescribed by the study doctor for 15 months

  • flexible dosing as prescribed by the study doctor for 15 months

  • flexible dosing as prescribed by the study doctor for 15 months

  • flexible dosing as prescribed by the study doctor for 15 months

  • 78, 117, 156, or 234 mg monthly injection for 15 months

  • flexible dosing as prescribed by the study doctor for 15 months

06

What researchers measure

Primary outcomes

  1. Time to First Treatment Failure

    Time to first treatment failure was the time from participant randomization to the first treatment failure, which was a composite endpoint consisting of any of the following events: arrest/incarceration, psychiatric hospitalization, discontinuation of antipsychotic treatment due to safety or tolerability, treatment supplementation with another antipsychotic due to inadequate efficacy, discontinuation of antipsychotic treatment due to inadequate efficacy, increase in level of psychiatric services to prevent imminent psychiatric hospitalization, suicide. A Treatment Failure Event Monitoring Board (EMB), blinded to individual participant treatment assignment, determined the occurrence and date of the first treatment failure event.

    Time frame: From date of randomization up to Month 15

  2. Percentage of Participants in Each Event Category of First Treatment Failure

    First treatment failure was a composite endpoint consisting of any of the following events: arrest/incarceration, psychiatric hospitalization, discontinuation (D/C) of antipsychotic treatment due to safety or tolerability, treatment supplementation with another antipsychotic due to inadequate efficacy, discontinuation of antipsychotic treatment due to inadequate efficacy, increase in level of psychiatric services to prevent imminent psychiatric hospitalization, suicide. A Treatment Failure Event Monitoring Board (EMB), blinded to individual participant treatment assignment, determined the occurrence and date of the first treatment failure event. Percentage of participants who experienced treatment failure due to any event and for each specific category of event were assessed.

    Time frame: From date of randomization up to Month 15

Secondary outcomes

  1. Time to First Psychiatric Hospitalization or Arrest/Incarceration

    A time to parameter looking only at 2 component events of treatment failure: arrest or incarceration, and psychiatric hospitalization. An arrest was defined as the taking of a participant into custody by legal authority, for any reason. Incarceration was defined as involuntary confinement by an officer of the law. Psychiatric hospitalization was an inpatient psychiatric hospitalization that occurred due to the participant's clinically significant worsening of symptoms of schizophrenia.

    Time frame: From date of randomization up to Month 15

  2. Change From Baseline in Personal and Social Performance (PSP) Total Score During Overall Treatment Duration

    The PSP score assesses the degree of difficulty a participant exhibit over a 1 month period within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior. The investigators rate participants' degree of difficulty in each of the 4 domains using a 6-point Likert scale (from 0=absent to 5=very severe). The domain ratings were then transformed to PSP total score ranging from 1 to 100. Higher PSP total scores denote better functioning. A score between 71 and 100 represents normal to mild degree of dysfunction; a score between 31 and 70 represents varying degree of difficulty; and a score \<=30 represents poor function that requires intensive supervision.

    Time frame: Baseline up to Month 15

  3. Time to First Psychiatric Hospitalization

    A time-to parameter looking only at 1 component event of treatment failure: psychiatric hospitalization. Time to first psychiatric hospitalization was admission date of the psychiatric hospitalization recorded in the "Assessment of Treatment Failure - Psychiatric Hospitalization."

    Time frame: From date of randomization up to Month 15

  4. Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score During Overall Treatment Duration

    The CGI-S rating scale was a 7-point global assessment of symptom severity with scores determined by clinician as follows: 1=Not ill, 2=Very Mild, 3= Mild, 4= Moderate, 5= Marked, 6= Severe, and 7= Extremely Severe. The higher the score the worse the illness.

    Time frame: Baseline up to Month 15

07

Results

Posted Dec 4, 2014

Participant flow

Participant flow — Overall Study
MilestonePaliperidone PalmitateOral Antipsychotics
Started230220
Treated226218
Completed9388
Not completed137132
Withdrew: Adverse event54
Withdrew: Death10
Withdrew: Lost to follow-up5355
Withdrew: Withdrawal by subject3727
Withdrew: Physician decision54
Withdrew: Protocol violation01
Withdrew: Other3236
Withdrew: Noncompliance with study drug03
Withdrew: Randomized but not treated42

Outcome measures

PrimaryTime to First Treatment Failure

Time to first treatment failure was the time from participant randomization to the first treatment failure, which was a composite endpoint consisting of any of the following events: arrest/incarceration, psychiatric hospitalization, discontinuation of antipsychotic treatment due to safety or tolerability, treatment supplementation with another antipsychotic due to inadequate efficacy, discontinuation of antipsychotic treatment due to inadequate efficacy, increase in level of psychiatric services to prevent imminent psychiatric hospitalization, suicide. A Treatment Failure Event Monitoring Board (EMB), blinded to individual participant treatment assignment, determined the occurrence and date of the first treatment failure event.

Time frame:
From date of randomization up to Month 15
Reported as:
Median · Days
Time to First Treatment Failure
DaysPaliperidone PalmitateOral Antipsychotics
Time to First Treatment Failure416 (285 to NA)226 (147 to 304)
SecondaryTime to First Psychiatric Hospitalization or Arrest/Incarceration

A time to parameter looking only at 2 component events of treatment failure: arrest or incarceration, and psychiatric hospitalization. An arrest was defined as the taking of a participant into custody by legal authority, for any reason. Incarceration was defined as involuntary confinement by an officer of the law. Psychiatric hospitalization was an inpatient psychiatric hospitalization that occurred due to the participant's clinically significant worsening of symptoms of schizophrenia.

Time frame:
From date of randomization up to Month 15
Reported as:
Median · Days
Time to First Psychiatric Hospitalization or Arrest/Incarceration
DaysPaliperidone PalmitateOral Antipsychotics
Time to First Psychiatric Hospitalization or Arrest/IncarcerationNA (NA to NA)274 (202 to 407)
SecondaryChange From Baseline in Personal and Social Performance (PSP) Total Score During Overall Treatment Duration

The PSP score assesses the degree of difficulty a participant exhibit over a 1 month period within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior. The investigators rate participants' degree of difficulty in each of the 4 domains using a 6-point Likert scale (from 0=absent to 5=very severe). The domain ratings were then transformed to PSP total score ranging from 1 to 100. Higher PSP total scores denote better functioning. A score between 71 and 100 represents normal to mild degree of dysfunction; a score between 31 and 70 represents varying degree of difficulty; and a score \<=30 represents poor function that requires intensive supervision.

Time frame:
Baseline up to Month 15
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Personal and Social Performance (PSP) Total Score During Overall Treatment Duration
Units on a scalePaliperidone PalmitateOral Antipsychotics
Change From Baseline in Personal and Social Performance (PSP) Total Score During Overall Treatment Duration5.75 ± 0.6905.36 ± 0.690
SecondaryTime to First Psychiatric Hospitalization

A time-to parameter looking only at 1 component event of treatment failure: psychiatric hospitalization. Time to first psychiatric hospitalization was admission date of the psychiatric hospitalization recorded in the "Assessment of Treatment Failure - Psychiatric Hospitalization."

Time frame:
From date of randomization up to Month 15
Reported as:
Median · Days
Time to First Psychiatric Hospitalization
DaysPaliperidone PalmitateOral Antipsychotics
Time to First Psychiatric HospitalizationNA (NA to NA)NA (NA to NA)
SecondaryChange From Baseline in Clinical Global Impression - Severity (CGI-S) Score During Overall Treatment Duration

The CGI-S rating scale was a 7-point global assessment of symptom severity with scores determined by clinician as follows: 1=Not ill, 2=Very Mild, 3= Mild, 4= Moderate, 5= Marked, 6= Severe, and 7= Extremely Severe. The higher the score the worse the illness.

Time frame:
Baseline up to Month 15
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score During Overall Treatment Duration
Units on a scalePaliperidone PalmitateOral Antipsychotics
Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score During Overall Treatment Duration-0.48 ± 0.038-0.43 ± 0.037
PrimaryPercentage of Participants in Each Event Category of First Treatment Failure

First treatment failure was a composite endpoint consisting of any of the following events: arrest/incarceration, psychiatric hospitalization, discontinuation (D/C) of antipsychotic treatment due to safety or tolerability, treatment supplementation with another antipsychotic due to inadequate efficacy, discontinuation of antipsychotic treatment due to inadequate efficacy, increase in level of psychiatric services to prevent imminent psychiatric hospitalization, suicide. A Treatment Failure Event Monitoring Board (EMB), blinded to individual participant treatment assignment, determined the occurrence and date of the first treatment failure event. Percentage of participants who experienced treatment failure due to any event and for each specific category of event were assessed.

Time frame:
From date of randomization up to Month 15
Reported as:
Number · percentage of participants
Percentage of Participants in Each Event Category of First Treatment Failure
percentage of participantsPaliperidone PalmitateOral Antipsychotics
Treatment Failure Due to Any Event39.853.7
Arrest/incarceration21.229.4
Psychiatric hospitalization8.011.9
D/C due to safety/tolerability6.63.7
Treatment supplementation2.22.8
D/C due to inadequate efficacy0.44.1
Increase in level of psychiatric services1.31.8
Suicide00

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Paliperidone Palmitate—42/226 (18.6%)178/226 (78.8%)
Oral Antipsychotics—53/218 (24.3%)155/218 (71.1%)
Most frequent serious events
Showing 10 of 79
Most frequent serious events
EventPaliperidone PalmitateOral Antipsychotics
SchizophreniaPsychiatric disorders4/22611/218
Suicidal IdeationPsychiatric disorders5/22611/218
Psychotic DisorderPsychiatric disorders11/2267/218
Schizophrenia, Paranoid TypePsychiatric disorders4/2265/218
DepressionPsychiatric disorders4/2261/218
Homicidal IdeationPsychiatric disorders0/2263/218
Suicide AttemptPsychiatric disorders1/2263/218
Acute PsychosisPsychiatric disorders1/2262/218
Renal Failure AcuteRenal and urinary disorders1/2262/218
CellulitisInfections and infestations2/2261/218
Most frequent other events
Showing 10 of 53
Most frequent other events
EventPaliperidone PalmitateOral Antipsychotics
Injection Site PainGeneral disorders42/2260/218
InsomniaPsychiatric disorders42/22627/218
Weight IncreasedInvestigations30/22616/218
AkathisiaNervous system disorders26/22617/218
AnxietyPsychiatric disorders25/22618/218
HeadacheNervous system disorders17/22619/218
DepressionPsychiatric disorders19/22617/218
Dry MouthGastrointestinal disorders15/22618/218
SedationNervous system disorders15/22618/218
FatigueGeneral disorders17/2266/218

Baseline characteristics

Intent to Treat (ITT) population included all participants who were randomly assigned to treatment and who received at least 1 dose of their randomly assigned study treatment.

Age, Continuous
Age, Continuous(years)Paliperidone PalmitateOral AntipsychoticsTotal
Mean37.7 ± 10.5738.6 ± 10.3638.1 ± 10.47
Sex: Female, Male
Sex: Female, Male(Participants)Paliperidone PalmitateOral AntipsychoticsTotal
Female332861
Male193190383
Baseline Personal and Social Performance (PSP) Total Score
Baseline Personal and Social Performance (PSP) Total Score(Units on a scale)Paliperidone PalmitateOral AntipsychoticsTotal
Mean54.8 ± 12.8355.0 ± 12.7354.9 ± 12.76
Baseline Clinical Global Impression - Severity (CGI-S) Total Score
Baseline Clinical Global Impression - Severity (CGI-S) Total Score(Units on a scale)Paliperidone PalmitateOral AntipsychoticsTotal
Mean3.8 ± 0.803.9 ± 0.703.8 ± 0.75
08

Study locations

56 sites
  • Bullhead City, Arizona, United States
  • Tuscon, Arizona, United States
  • Little Rock, Arkansas, United States
  • Anaheim, California, United States
  • Escondido, California, United States
  • Glendale, California, United States
  • Imperial, California, United States
  • Long Beach, California, United States
  • National City, California, United States
  • Oakland, California, United States
  • Oceanside, California, United States
  • Pico Rivera, California, United States
  • Riverside, California, United States
  • San Bernadino, California, United States
  • San Diego, California, United States
  • San Fran Cisco, California, United States
  • New Britain, Connecticut, United States
  • New London, Connecticut, United States
  • Leesburg, Florida, United States
  • Miami Gardens, Florida, United States
  • Miami, Florida, United States
  • Pensacola, Florida, United States
  • Tamarac, Florida, United States
  • Tampa, Florida, United States
  • Honolulu, Hawaii, United States
  • Chicago, Illinois, United States
  • Hoffman Estates, Illinois, United States
  • Naperville, Illinois, United States
  • Springfield, Illinois, United States
  • Wichita, Kansas, United States
  • Witchita, Kansas, United States
  • New Orleans, Louisiana, United States
  • Shreveport, Louisiana, United States
  • Flowood, Mississippi, United States
  • Kansas City, Missouri, United States
  • Omaha, Nebraska, United States
  • Las Vegas, Nevada, United States
  • Paramus, New Jersey, United States
  • Willingboro, New Jersey, United States
  • Buffalo, New York, United States
  • New York, New York, United States
  • Cleveland, Ohio, United States
  • Middleburg Heights, Ohio, United States
  • Willoughby, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Allentown, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Nashville, Tennessee, United States
  • Desoto, Texas, United States
  • Irving, Texas, United States
  • San Antonio, Texas, United States
  • Wharton, Texas, United States
  • Bothell, Washington, United States
  • Spokane, Washington, United States
  • Rio Piedras, Puerto Rico
09

References and documents

Publications

  • Bell Lynum KS, Henderson DC, Wright HJ, Gogate JP, Kim E. Treatment Effect With Paliperidone Palmitate Compared With Oral Antipsychotics in Black/African American Patients With Schizophrenia and a History of Criminal Justice System Involvement: A Post Hoc Analysis of the PRIDE Study. J Clin Psychiatry. 2021 Feb 23;82(2):20m13356. doi: 10.4088/JCP.20m13356. PubMed 33988924 ↗
  • Alphs L, Mao L, Lynn Starr H, Benson C. A pragmatic analysis comparing once-monthly paliperidone palmitate versus daily oral antipsychotic treatment in patients with schizophrenia. Schizophr Res. 2016 Feb;170(2-3):259-64. doi: 10.1016/j.schres.2015.12.012. Epub 2015 Dec 29. PubMed 26742509 ↗
  • Alphs L, Bossie C, Mao L, Lee E, Starr HL. Treatment effect with paliperidone palmitate compared with oral antipsychotics in patients with recent-onset versus more chronic schizophrenia and a history of criminal justice system involvement. Early Interv Psychiatry. 2018 Feb;12(1):55-65. doi: 10.1111/eip.12271. Epub 2015 Sep 25. PubMed 26403322 ↗
  • Alphs L, Benson C, Cheshire-Kinney K, Lindenmayer JP, Mao L, Rodriguez SC, Starr HL. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study. J Clin Psychiatry. 2015 May;76(5):554-61. doi: 10.4088/JCP.14m09584. PubMed 25938474 ↗
  • Alphs L, Mao L, Rodriguez SC, Hulihan J, Starr HL. Design and rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study: a novel comparative trial of once-monthly paliperidone palmitate versus daily oral antipsychotic treatment for delaying time to treatment failure in persons with schizophrenia. J Clin Psychiatry. 2014 Dec;75(12):1388-93. doi: 10.4088/JCP.13m08965. PubMed 25375367 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2010, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2014, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2010
First posted
Jul 7, 2010
Start
May 2010
Primary completionActual
Dec 2013
CompletionActual
Dec 2013
Results first posted
Dec 4, 2014
Last update
Apr 24, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01157351
Responsible party
Sponsor
First posted
Jul 7, 2010
Start date
May 2010
Primary completion
Dec 2013
Completion
Dec 2013
Results posted
Dec 4, 2014
Last update
Apr 24, 2015

Study contacts

Janssen Scientific Affairs, LLC Clinical Trial
study director · Janssen Scientific Affairs, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paliperidone

Start the discussion